do glp-1 cause cancer Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management Protecting the endocrine axis in

Disclosures: Hee Sun Cho: Nothing to Disclose, Jaejun Lee: Nothing to Disclose, Ah Lim Lee: Nothing to Disclose, Hyun Yang: Nothing to Disclose 1111 A PROSPECTIVE ASSESSMENT OF THE IMPACT OF DECOMPENSATION OF CIRRHOSIS ON PATIENT-REPORTED OUTCOMES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Ian O'Connor 1 Andrea Mospan 2 Cheryl Schoen 2 Alfred Barritt IV 3 Arun Sanyal 1 , 1 Virginia Commonwealth University, 2 Target RWE, 3 University of North Carolina Background: Metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD and MASH) are major causes of liver-related morbidity and mortality

3,4 Another agent gaining in popularity is tirzepatide (Mounjaro, Zepbound), a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA

This group is known as a class. The class represents the interests of a larger group of people with similar injuries and claims

Jastreboff, L

Ophthalmic Epidemiol